Genetically modified T-cell therapy granted enhanced EMA regulatory pathway: KTE-C19

Kite Pharma granted access to PRIME regulatory support for KTE-C19 to treat chemorefractory DLBCL In a press release, Kite Pharma announced that it is?among first sponsors selected to participate in the EMAs enhanced regulatory program for investigational therapies that promise significant advances against serious diseases. ?The?European Medicines Agency (EMA) Committee for Medicinal Products for Human[…]

New data on chemotherapy resistance in ovarian cancer

University of Michigan The new study’s author,?J. Rebecca Liu, M.D., associate professor of obstetrics and gynecology at the University of Michigan, is quoted as saying?”In the past, we?ve thought (chemotherapy) resistance was caused by genetic changes in tumor cells. But we found that?s not the whole story.” ??@MHealthLab ?@3SixtyPharma ?#3SixtyPharmaSME